8-K: Anteris Raises $25M, Advances Pivotal TAVR Trial

Anteris Technologies Global Corp. secured approximately US$25 million in gross proceeds through an equity offering to fund its pivotal PARADIGM Trial for its biomimetic DurAVR THV.

Summary

• Anteris Technologies Global Corp. completed an equity offering raising approximately US$25 million in aggregate gross proceeds.
• The offering included the sale of 2,244,896 shares of common stock and accompanying five-year warrants at US$4.90 per share/warrant, and 2,788,064 CHESS Depositary Interests (CDIs) and accompanying five-year warrants at A$7.50 per CDI/warrant.
• The Common Stock Warrants have an exercise price of $7.50 per share, and CDI Warrants have an exercise price of A$11.50 per CDI, both exercisable six months post-issuance.
• The company is advancing its DurAVR THV, a proprietary biomimetic balloon-expandable TAVR, with 130 patients treated to date, including 49 patients treated year-to-date in 2025.
• The pivotal PARADIGM Trial, an all-risk, head-to-head TAVR registration trial, is targeted to commence First Patient In (FPI) in Q4 2025, subject to regulatory approval.
• DurAVR THV aims to restore curative, pre-disease hemodynamics and has shown a 29% reduction in Left Ventricular Mass Index in Early Feasibility Study data.

Sentiment

Score: 8

Explanation: The filing details a successful capital raise and significant progress in clinical trials for a promising medical device in a large market. While there are regulatory risks and potential delays, the overall outlook is positive due to funding, strong clinical data, and a clear path to commercialization.

Positives

• Successful capital raise of approximately US$25 million, strengthening the financial position for clinical development and operations.
• Advancement of the DurAVR THV, a proprietary, first-in-class biomimetic TAVR designed for younger, more active patients.
• Positive clinical validation with 130 patients treated, demonstrating strong 30-day and 1-year performance.
• DurAVR THV showed sustained hemodynamic performance to 1 year, with a mean pressure gradient of 8.6 mmHg, effective orifice area of 2.1 cm², and Doppler Velocity Index of 0.58.
• The DurAVR THV is the first aortic valve to restore normal aortic flow, showing no significant difference in flow compared to a healthy aortic valve (p>0.05).
• Significant 29% reduction in Left Ventricular Mass Index observed in Early Feasibility Study data.
• Pivotal PARADIGM Trial targeted to launch in Q4 2025, potentially leading to FDA and CE Mark approvals.
• Established manufacturing footprint and a highly experienced leadership team in clinical, operational, and commercial areas.
• The global TAVR market is forecasted to reach US$9.9 billion by 2028 (US$12.5 billion with Valve-in-Valve), with 80-85% of severe aortic stenosis patients currently untreated, indicating significant market opportunity.

Risks

• Forward-looking statements are subject to risks, uncertainties, and assumptions, including those described in the company's Annual Report on Form 10-K for the fiscal period ended December 31, 2024.
• The FDA has provided requests for additional information regarding the DurAVR IDE Submission for the PARADIGM Trial, and approval is not guaranteed on any particular timeline.
• Prolonged government shutdown or disruption could significantly impact the FDA's ability to timely review and process regulatory submissions.
• If the PARADIGM Trial commences in a non-U.S. jurisdiction prior to FDA IDE approval, and the FDA-approved IDE version differs from the version tested, the trial results may not be permitted to be used to support a future FDA marketing approval.
• Milestones are forward-looking goals subject to significant business, economic, regulatory, and competitive uncertainties and contingencies, and actual results may vary materially.

Future Outlook

Anteris Technologies expects the Common Stock Offering to close around October 27, 2025, and the CDI Offering to settle around October 30, 2025, generating approximately US$25 million in gross proceeds. The company targets FDA IDE approval for its pivotal PARADIGM Trial in Q4 2025, with the First Patient In (FPI) for the trial also targeted for Q4 2025. A CE Mark submission for DurAVR is anticipated in Q2 2026, and patient recruitment for the all-risk cohort of the PARADIGM Trial is expected to be completed by Q4 2026. The company aims for PMA submission based on 1-year clinical data from the all-comers randomized cohort.

Management Comments

• "A balloon expandable valve with self-expanding hemodynamics is like the holy grail." Dr. Michael Reardon, Professor of Cardiothoracic Surgery, Allison Family Distinguished Chair of Cardiovascular Research, Methodist DeBakey Heart & Vascular Center.

Industry Context

The TAVR market is projected to reach US$9.9 billion by 2028, with a significant underpenetrated patient population (80-85% of severe aortic stenosis patients untreated). Anteris's DurAVR THV is positioned as a new class of TAVR, specifically designed to mimic a healthy aortic valve and address the needs of younger, more active patients, differentiating itself from existing first and second-generation TAVRs that were developed for older patient populations. The company aims to disrupt this high-value, growth market by offering curative, pre-disease hemodynamics.

Comparison to Industry Standards

• DurAVR THV is presented as the only biomimetic balloon-expandable TAVR, aiming to deliver curative, pre-disease hemodynamics, unlike existing TAVRs such as Edwards Lifesciences' SAPIEN series or Medtronic's Evolut series.
• DurAVR THV showed no significant difference in flow (p>0.05) when compared to a healthy aortic valve, a claim not made by other TAVR devices mentioned (Sapien 3, CEP Magna Ease, Evolut R) which showed impaired aortic flow.
• The PARADIGM Trial is designed as an all-risk, head-to-head TAVR registration trial, comparing DurAVR THV against SAPIEN or Evolut series THVs, indicating direct competition with market leaders.
• The Valve-in-Valve (ViV) market, projected at US$2.5 billion by 2028, is a key area where DurAVR's short-frame valve and large open cell geometry are highlighted as solutions for challenges like preserving coronary access, which is a known issue with other valves in ViV procedures.

Management Changes

Related Party Transactions

• Evolution Capital Pty Ltd acted as lead manager for the CDI Offering and will be issued 250,000 CDI Warrants.

Stakeholder Impact

• Shareholders: Experience dilution from the equity offering, but benefit from a strengthened financial position for clinical development. Potential for significant value creation if DurAVR THV achieves regulatory approval and commercial success.
• Investors (new): Opportunity to invest in a company with a promising medical device and a clear path to market, albeit with inherent clinical trial and regulatory risks.
• Patients: Potential for a new, improved treatment option for aortic stenosis, especially for younger and more active patients, offering better hemodynamic outcomes.
• Employees: Continued employment and potential growth opportunities as the company advances towards commercialization.
• Regulatory Authorities: Ongoing engagement with FDA and European regulatory bodies for IDE approval and CE Mark.

Next Steps

• Closing of Common Stock Offering around October 27, 2025.
• Settlement of CDI Offering around October 30, 2025.
• Address FDA requests for additional information regarding the DurAVR IDE Submission for the PARADIGM Trial.
• Targeted DurAVR IDE approval for PARADIGM Trial in Q4 2025.
• Targeted First Patient In (FPI) for the pivotal PARADIGM Trial in Q4 2025.
• Various presentations at TCT, EACTS, PCR LV in Q4 2025.
• Presentations at CRT, THT, ACC in Q1 2026.
• DurAVR CE Mark Submission and PCR presentation in Q2 2026.
• PARADIGM EU Investigator Meeting in Q3 2026.
• PARADIGM Trial Last Patient In (LPI) for all-risk patient cohort in Q4 2026.
• Prepare and file a registration statement with the SEC covering the resale of offered securities.
• 1-year data from the all-comers randomized cohort of the PARADIGM Trial will be used to support PMA submission.
• Continued access for low-risk randomized cohort and standalone Valve-in-Valve registry.

Key Dates

Recommendation

The successful US$25 million capital raise significantly de-risks Anteris's financial position, providing crucial funding for the pivotal PARADIGM Trial. The DurAVR THV demonstrates compelling clinical data, including superior hemodynamics and LV mass regression, positioning it as a potential 'new class' TAVR in a large and underpenetrated market. While regulatory hurdles and potential delays exist, the clear path to FDA and CE Mark approvals, combined with a highly experienced management team and a capital-efficient commercialization strategy, suggests strong upside potential for long-term investors. The company is addressing a critical unmet need for younger, more active patients, which could lead to substantial market penetration upon approval.

Keywords

Anteris Technologies, AVR, TAVR, DurAVR THV, Aortic Stenosis, PARADIGM Trial, SEC Filing, Equity Offering, Warrants, Biomimetic Valve, Cardiovascular, Medical Devices, FDA Approval, CE Mark, Capital Raise